Michael Jung

FDA passes enzalutamide (Xtandi®) For Treatment Of An Advanced Cancer

The US Food and Drug Administration (FDA) has approved a product known as enzalutamide (Xtandi®) to be used in a new way. The body, after an in-depth review says that it is ideal for handling a condition called prostate cancer (mHSPC). A close outlook Sometime back, the company gave its approval to the product for […]